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Abstract
Background: Hemodynamically irrelevant pericardial effusion (PeEf) is a predictor of adverse outcome in 
heart failure patients. The clinical relevance of a PeEf unrelated to surgery in heart transplant patients remains 
unknown. This study assesses the prognostic value of PeEf occurring later than 1 year after transplantation.
Methods: All patients undergoing heart transplantation in Zurich between 1989 and 2012 were screened. 
Cox proportional hazard models were used to analyze mortality (primary) and hospitalization (secondary 
endpoint). PeEf time points were compared to baseline for rejection, immunosuppressants, tumors, inflam-
mation, heart failure, kidney function, hemodynamic, and echocardiographic parameters.
Results: Of 152 patients (mean age 48.3 ± 11.9), 25 developed PeEf. Median follow-up period was 
11.9 (IQR 5.8–17) years. The number of deaths was 6 in the PeEf group and 46 in the non-PeEf 
group. The occurrence of PeEf was associated with a 2.5-fold increased risk of death (HR 2.49, 95% CI 
1.02–6.13, p = 0.046) and hospitalization (HR 2.53, 95% CI 1.57–4.1, p = 0.0002).
Conclusions: This study reveals that the finding of hemodynamically irrelevant PeEf in heart trans-
plant patients is a predictor of adverse outcome, suggesting that a careful clinical assessment is war-
ranted in heart transplant patients exhibiting small PeEf. (Cardiol J 2018; 25, 6: 714–721)
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Introduction
Pericardial effusion (PeEf) is a common find-
ing in the acute phase after heart transplantation 
[1]. During the first months, moderate to severe 
PeEf has been described in up to 21% of patients 
and has been subject of several studies [2–4]. In 
contrast, the development of PeEf later than 1 year 
after heart transplantation is rare [5] and its clinical 
significance has not been investigated. 
Small and hemodynamically irrelevant PeEf, 
which may be observed during routine echocardio-
graphy [5], is associated with increased mortality 
in patients with chronic heart failure [6] as well as 
in those with pulmonary hypertension [7]. How-
ever, in patients after heart transplantation, the 
prognostic value of a hemodynamically irrelevant 
PeEf not related to surgery remains undetermined. 
Thus, the aim of this study was to assess the prog-
nostic significance of this finding in patients 1 year 
or later after heart transplantation.
Methods
Patient population and baseline  
characteristics
All patients undergoing heart transplantation 
at the University Heart Center Zurich between 
August 1989 and July 2012 were retrospectively 
screened for inclusion in this study. Exclusion 
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criteria were death within the first year after trans-
plantation, age < 16 years at heart transplantation, 
and lack of echocardiography studies. Baseline was 
defined as the time of the first echocardiography 
study later than 1 year after heart transplantation. 
Data on age, gender, body weight, blood pres-
sure, heart rate, primary heart disease (ischemic 
vs. non-ischemic), New York Heart Association 
(NYHA) functional class, International Society for 
Heart and Lung Transplantation (ISHLT) score, 
medication, and laboratory values were retrieved 
from local databases and patient records. Survival 
and hospitalization data was retrieved from the 
post-transplant database and completed by detailed 
reviewing of electronic medical records as well as 
paper charts from the heart transplantation unit of 
the University Heart Center Zurich. The study was 
approved by the local ethical committee and com-
plies with the Declaration of Helsinki. Informed 
consent was obtained from all subjects.
Study groups and outcome measures
Patients with no signs of PeEf were defined as 
the control group. Patients exhibiting a PeEf were 
assigned to the PeEf group at the first time point 
the PeEf was detected and remained in this group 
until the end of the study. Hence, with each occur-
rence of a PeEf, the composition of the two groups 
changes, as a patient moves from the control to the 
PeEf group. The primary outcome measure was all-
cause mortality. The secondary outcome measure 
was unscheduled hospitalization for any cause.
Echocardiography
All echocardiograms available were included 
in the analysis and were analyzed independently 
by two experienced physicians. In general, echocar-
diograms were performed when applicable every 
2 years, additionally  whenever clinically indicated. 
The presence of a hemodynamically irrelevant PeEf 
was defined as an end-diastolic hypoechogenic space 
in the pericardium without signs of hemodynamic 
compromise (inversion or collapsing of right side 
heart chambers, abnormal ventricular septal mo-
tion, respiratory variation of mitral inflow > 25%). 
Other echocardiographic parameters were analyzed 
according to guidelines of the European Society 
of Cardiology [8] including grading of mitral and 
tricuspid regurgitation, tricuspid annular plane 
systolic excursion (TAPSE), mitral annular plane 
systolic excursion, left ventricular end-diastolic 
volume and ejection fraction, end-diastolic diameter, 
end-systolic diameter, left ventricular mass index, 
left atrial end-systolic diameter, right ventricular (RV) 
end-diastolic diameter, right atrial dimensions 
(RA long and short axis), fractional area change, 
and systolic RV-RA pressure gradient (∆p RV-RA).
Laboratory and histological parameters
Blood samples were taken during clinical rou-
tine follow-up (usually every 6 months in the heart 
failure and heart transplantation clinic) as well as 
during unscheduled hospitalization. C-reactive 
protein and creatinine levels were analyzed using 
the Cobas analyser (Roche Diagnostics, Basel, 
Switzerland) at the Institute of Clinical Chemistry 
of the University Hospital Zurich.
Right ventricular septal endomyocardial biop-
sies were performed according to the post-trans-
plant surveillance program of the documented heart 
transplantation clinic and cardiac cellular allograft 
rejection grading was performed according to the 
ISHLT guidelines [9]. In general, endomyocardial 
biopsies were performed when applicable every 
6 months, additionally when otherwise indicated.
Statistical analysis
Statistical analysis was performed by the Epi-
demiology, Biostatistics and Prevention Institute in 
the Department of Biostatistics at the University of 
Zurich. The time-dependent variable PeEf was taken 
into account as described in Anderson et al. 1983 [10] 
(“Mantel-Byar Approach”) and Andersen 1992 [11], 
and modelled with a Cox regression with age as time 
scale and with or without adjustment for age at trans-
plantation and gender. Transition from non-PeEf to 
PeEf group was taken into account by creating a data 
set listing the time-dependent group variable for each 
follow-up visit of  patients and the time span during 
which the assignment to a group did not change. In 
this model, all patients belong to the group without 
PeEf at the beginning of the observation and shift 
to the other group, as soon as they develop PeEf. 
Thus, groups are not constant and direct statistical 
comparison of the groups with the final distribution 
was not performed. Statistical analysis of not nor-
mally distributed parameters at baseline vs. time 
of PeEf was performed using the Wilcoxon signed-
rank test. A p-value < 0.05 was considered statisti-
cally significant. As statistical software, the R pro- 
gramming language [12] Version 3.4.1 was applied.
Results
Patient population  
and echocardiography findings
All 313 patients undergoing heart transplanta-
tion at the University Heart Center Zurich between 
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August 1989 and July 2012 were evaluated for this 
study. Exclusion criteria were death within the first 
year after transplantation (64 patients), age < 16 
years at heart transplantation (8 patients), and lack 
of echocardiography studies (89 patients, mostly 
due to follow up in other hospitals). A total of 152 
patients were included in the study (Suppl. Fig. 1). 
Clinical baseline characteristics of the study popu-
lation are displayed in Table 1. Most of the patients 
were male (84.9%) and had transplants due to 
non-ischemic heart disease (65%). Mean age at 
transplantation was 48.3 ± 11.9 years. Median 
follow-up duration was 11.9 (interquartile range 
[IQR] 5.8–17) years.
Baseline echocardiography was performed 
after a median of 3 (IQR 1.5–9.5) years post heart 
transplantation. Echocardiographic baseline char-
acteristics are displayed in Table 1. Moderate or 
severe tricuspid regurgitation was frequent (n = 22, 
15.2%). Twenty-five patients developed PeEf 
over time with a PeEf incidence of 14.4 per 1000 
patient-years. First diagnosis of PeEf occurred after 
a median of 11.1 (IQR 4.1–14) years after heart 
transplantation. Hemodynamically relevant PeEf 
did not occur in any patients. Except for one, all 
PeEf were small with a maximal width of 1 cm in 
diastole. The one large (but also hemodynamically 
irrelevant) PeEf exhibited spontaneous regression 
without recurrence. At the time of occurrence, 
broad examinations revealed that it was most likely 
triggered by a viral polyserositis.
Direct comparison of patient groups was not 
legitimate since patients exhibiting a PeEf were 
assigned to the PeEf group at the first time point 
when PeEf was detected and remained in this group 
until the end of the study. Hence, with each occur-
rence of PeEf, the composition of the two groups 
changed (as described in the methods section).
Mortality
The total number of deaths was 6 in pa-
tients with PeEf and 46 in those without PeEf. 
When adjusted for age at transplantation and 
gender, the occurrence of PeEf was associated 
with a 2.5-fold increase in the risk of death (ad-
justed hazard ratio [HR] 2.49, 95% confodence 
interval [CI] 1.02–6.13, p = 0.046). In the un-
adjusted analysis, there was a trend towards 
increased mortality (unadjusted HR 2.27, 95% CI 
0.95–5.47, p = 0.066). The probability of survival 
for patients with PeEf as compared to patients 
never developing PeEf is depicted in Figure 1A 
(for demonstration purposes, the time-point of first 
PeEf is hypothetically set to baseline).
Causes of death are depicted in Figure 1B. Can-
cer was the main reason for death (n = 15, 28.8%), 
followed by infection (n = 8, 15.4%), heart failure 
(n = 7, 13.4%), and cardiac allograft vasculopathy 
(n = 4, 7.7%). In 2 (3.8%) patients, rejection, 
bleeding, or renal failure was the cause of death, 
respectively. Other causes of death included 
2 perioperative complications, 1 documented arrhy-
thmia, 1 pulseless electrical activity, and 1 stroke. In 
7 patients, death occurred for unknown reasons.
Hospitalization
The absolute number of unscheduled hospi-
talizations was 42 in patients with PeEf and 136 in 
Table 1. Baseline characteristics of all patients.
Baseline n
Clinical parameters
Age [years] 48.3 ± 11.9 152
Male 129 (84.9%) 152
BMI [kg/m2] 26.3 ± 5.1 145
Systolic BP [mmHg] 136.5 ± 15.4 28
Heart rate [bpm] 85.7 ± 13.1 139
IHD 53 (34.9%) 152
Non-IHD 99 (65.1%) 152
Echocardiography
LVEF [%] 60.9 ± 7.4 122
LV EDV [mL] 89.7 ± 23.4 98
LV EDD [mm] 47 ± 5.1 135
LV ESD [mm] 29 ± 5.5 134
LVMI [g/m2] 98.4 ± 27.7 102
LA ESD [mm] 48 ± 10 136
MAPSE [mm] 15.6 ± 2.8 60
Mitral regurgitation:  
≥ moderate
1 (0.7%) 143
TR: moderate 13 (9.0%) 145
TR: severe 9 (6.2%) 145
FAC [%] 43.2 ± 9.3 51
TAPSE [mm] 18.4 ± 4.3 66
RVEDD [mm] 32 ± 6.5 94
RA long axis [mm] 53 ± 9 124
RA short axis [mm] 39 ± 7.5 119
∆p RV-RA [mmHg] 27.1 ± 8.1 117
Values presented as mean mean ± standard deviation or number 
and percentage;  BMI — body mass index; BP — blood pressure; 
EDD — end-diastolic diameter; EDV — end-diastolic volume;  
ESD — end-systolic diameter; FAC — fractional area change;  
IHD — ischemic heart disease; LA — left atrium; LV — left ventricle; 
LVEF — left ventricular ejection fraction; LVMI — left ventricular 
mass index; MAPSE — mitral annular plane systolic excursion;  
RA — right atrium; RV — right ventricle; TAPSE — tricuspid annular 
plane systolic excursion; TR — tricuspid regurgitation;  
∆p — pressure gradient
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patients without PeEf. Median interval between 
transplantation and the first unscheduled hospitali-
zation was 5.6 (IQR 3–10) years. Median duration 
of hospitalization was 8 (IQR 6-15) days. In a Cox 
proportional hazard model, the risk of being admit-
ted for hospitalization was significantly increased in 
patients exhibiting a prior PeEf compared to patients 
without PeEf (unadjusted HR 2.53, 95% CI 1.57–4.1, 
p = 0.0002). Figure 2A compares the probability 
of freedom from unscheduled hospitalization in 
patients with PeEf with patients never developing 
PeEf (for demonstration purposes, the time-point of 
first PeEf is hypothetically set to baseline). 
The main reason for hospitalization (Fig. 2B) 
was infection (n = 137, 47.6%), followed by a het-
erogeneous group of predominantly arterial and 
venous cardiovascular problems (n = 30, 10.4%) 
and cancer (n = 20, 6.9%). No hospitalizations were 
because of  pericardial effusion.
Characterization of patients  
at the time of pericardial effusion
To evaluate possible causes of PeEf, patients 
developing PeEf were characterized in more detail. 
Paired analysis for comparison of various param-
eters at the time of PeEf versus baseline revealed 
no difference for most parameters (Table 2). In 
particular, rejection stage, inflammation param-
eters, renal function, left ventricular function, right 
ventricular dimensions and tricuspid regurgitation 
were comparable at both time points.
NYHA functional class exhibited a trend to-
wards higher stages at the time of PeEf as com-
pared to baseline (median 1 IQR 1–1.875 vs. 2 IQR 
1.125–2, p = 0.053, n = 14), whereas the N-ter-
minal fragment of prohormone B-type natriuretic 
peptide (NT-proBNP) did not differ significantly. 
Left atrial size as assessed by left atrial-end-sys-
tolic diameter was larger at the time of PeEf (me-
dian 4.05 IQR 3.75–5.1 vs. 5.2 IQR 4.38–5.55 cm, 
p = 0.021, n = 12). Systolic blood pressure was 
reduced at the time of PeEf (median 136.5 IQR 
130–142 vs. 117.5 IQR 111.2–128 mmHg; p = 0.004, 
n = 14). Longitudinal shortening of the right ven-
tricle as assessed by TAPSE was also decreased 
under these conditions (median 18 IQR 18–22 vs. 
17 IQR 15–19 mm, p = 0.033, n = 7).
The temporal relationship between the detec-
tion of PeEf and the time of transplantation was 
also evaluated. There was a linear increase in the 
number of patients affected by a PeEf with time 
after transplantation. No association pattern was 
detectable regarding the incidence of PeEf and the 
time after transplantation (Fig. 3A). Similarly, the 
incidence of malignant tumors was examined in 
relation to the time-point of PeEf. No association 
was evident between the incidence of malignant 
tumors and that of PeEf (Fig. 3B). Immunosuppres-
Figure 1. A. Separate estimated survivor functions for patients after heart transplantation. The solid black line is the 
survivor function for patients without pericardial effusion; the broken line is for patients who showed at least once 
a pericardial effusion (for demonstration purposes, the time-point of first pericardial effusion is hypothetically set to 
baseline); B. Cause of death in all patients (52 deaths).
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Figure 2. A. Separate estimated functions depicting freedom from unscheduled admission to a hospital for patients 
after heart transplantation. The solid black line is the function for patients without pericardial effusion; the broken line 
is for patients who showed at least once a pericardial effusion (for demonstration purposes, the time-point of first 
pericardial effusion is hypothetically set to baseline); B. Cause of hospitalization in all patients (137 hospitalizations).
Table 2. Analysis of parameters at baseline vs. time of pericardial effusion (PeEf) in patients developing 
a PeEf and having the parameters assessed at both time points. 
Baseline Time of PeEf P n
Rejection 
ISHLT stage 1.0 (0.0–1.0) 1.0 (0.0–1.0) NS 13
Inflammation and kidney function
CRP [mg/L] 3.0 (1.50–10.55) 19.0 (3.05–67.00) NS 15
Leucocytes [G/L] 6.75 (4.94–8.16) 6.34 (5.02–8.15) NS 17
Creatinine [μmol/] 156 (142–179) 131 (104–219) NS 17
Heart failure 
NYHA class [1–4] 1.00 (1.00–1.875) 2.00 (1.125–2.00) 0.053 14
Body weight [kg] 79.0 (68.3–89.8) 76.0 (67.0–89.0) NS 16
NT-proBNP [ng/L] 465 (146–1577) 534 (166–2555) NS 13
Blood pressure and heart rate 
Systolic BP [mmHg] 136.5 (130.0–142.0) 117.5 (111.2–128.0) 0.004 14
Heart rate [bpm] 91 (80–98) 88 (79–91) NS 14
Echocardiography
LVEF [%] 62.5 (60.0–64.0) 61.5 (59.0–64.8) NS 14
LAESD [cm] 4.05 (3.75–5.10) 5.20 (4.38–5.55) 0.021 12
Mitral regurgitation (1–4) 1.0 (1.0–1.0) 1.0 (1.0–2.0) NS 14
Tricuspid regurgitation (1–4) 1.0 (1.0–2.0) 2.0 (1.0–2.0) NS 16
∆p RV-RA [mmHg] 25.0 (20.0–28.5) 28.0 (22.0–29.0) NS 11
TAPSE [mm] 18 (18–22) 17 (15–19) 0.033 7
Values are presented as median (1st–3rd quartile). BP — blood pressure; CRP — C-reactive protein; ISHLT — International Society for Heart and 
Lung Transplantation; LAESD — left atrial end-systolic diameter; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal fragment 
of prohormone B-type natriuretic peptide; NYHA — New York Heart Association; RA — right atrium; RV — right ventricle; TAPSE — tricuspid 
annular plane systolic excursion; ∆p — pressure gradient
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sant medication was comparable at baseline and 
time of PeEf (Table 3). Sirolimus was prescribed 
in 3 patients at the time of PeEf whereas it was not 
prescribed at baseline.
Discussion
This study reveals that the presence of 
a hemodynamically irrelevant PeEf occurring 
unrelated to surgery in heart transplant patients 
is a predictor of mortality and unscheduled hos-
pitalization. PeEf occurring during the first year 
after heart transplantation were not included in 
this analysis since PeEf in this period is usually 
related to surgery, resolves spontaneously [2, 13] 
usually within 3 months, and is associated with 
recipient-donor weight mismatch and possibly 
rejection [1–3, 14, 15].
In this study, the incidence of PeEf was 14.4 
per 1000 patient-years during follow-up. No as-
sociation of PeEf with the time after transplanta-
tion was observed. This is in contrast to another 
study demonstrating a continuous decrease in 
the incidence of PeEf after transplantation [5]. 
In that study, however, the first year after trans-
plantation was included and the average follow-up 
was no more than 3 years, suggesting that many 
surgery-related PeEf were considered. This type 
of PeEf is a common finding and associated with 
transplantation-independent surgical risk [16]. In 
the present population, however, about half of the 
PeEf not related to surgery occurred more than 
10 years after transplantation.
It was observed that patients with PeEf were 
at a 2.5-fold higher risk of death than those remaining 
free of PeEf. This is in line with studies assessing 
the prognostic value of PeEf in patients with heart 
failure [6] or pulmonary hypertension [7]. In patients 
with or without PeEf, the main causes of death were 
cancer and infections, followed by heart failure and 
cardiac allograft vasculopathy. This is consistent with 
the latest report of The Registry of the International 
Society for Heart and Lung Transplantation report-
ing malignant tumors, rejection-independent graft 
failure, infection, cardiac allograft vasculopathy, and 
failure of other organs as the main reasons for long-
term mortality in heart transplant recipients [17]. 
These findings suggest that the PeEf observed in 
the present population might not be associated with 
a specific pathologic condition but rather be a general 
prognostic indicator for a worse clinical course.
To further characterize the prognostic value of 
small PeEf, hospitalization rates were studied. The 
hazard of being hospitalized was 2.5-fold higher in 
patients diagnozed with PeEf at any time compared 
to patients without PeEf. The steep decrease (Fig. 2A) 
in the probability for remaining free of hospitali-
zation in the PeEf group early during observation 
is mainly driven by a single patient who had 
a PeEf documented on day 485 and was subsequently 
hospitalized three times in rapid succession due to 
causes not related to PeEf. Exclusion of this pa-
tient, however, did not alter the results significantly 
(HR 2.24, 95% CI 1.33–3.77). Infection was the 
reason for almost half of hospitalizations, followed 
by cardiovascular complications, cancer, and rejec-
tion. Similar to these findings, infections have been 
reported to be the leading cause for hospitalization 
during the first 5 years after transplantation [17].
Figure 3. A. Diagnosis of pericardial effusion (PeEf) (blue 
lines) and its temporal relation to heart transplanta-
tion (dotted line) in all patients with PeEf; 25 patients, 
30 PeEf; B. Diagnosis of malignant tumors (blue lines) 
and its temporal relation to first PeEf (dotted line) in all 
patients with PeEf and tumor diagnosis; 15 patients, 
30 tumors.
Table 3. Specific immunosuppressant therapy 
at baseline versus at time of pericardial effusion 
(PeEf) (all patients who developed a PeEf).
Medication Baseline Time of PeEf
Ciclosporin 12 (71%) 15 (60%)
Azathioprine 11 (65%) 13 (52%)
Cortisone 9 (53%) 12 (48%)
Mycophenolic acid 6 (35%) 10 (40%)
Tacrolimus 5 (29%) 6 (24%)
Everolimus 2 (12%) 1 (4%)
Sirolimus 0 (0%) 3 (12%)
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To evaluate possible causes for the develop-
ment of PeEf, patients with PeEf were analyzed 
in detail. At the time-point of PeEf no difference 
was observed when compared to baseline for most 
parameters such as rejection stage, inflammation 
parameters, renal function, left ventricular func-
tion, right ventricular size, and tricuspid regurgi-
tation. NYHA functional class and left atrial size, 
however, were elevated, whereas NT-proBNP 
remained unchanged. This discrepancy may be due 
to the fact that the NYHA classification evaluates 
the occurrence of symptoms which are often, but 
not exclusively, due to heart failure [18]. Several 
studies showed that different comorbidities like 
depression [19], anaemia, chronic obstructive pul-
monary disease, and others [20] can significantly 
reduce NYHA functional class. Thus, alterations 
in NYHA functional class can be multifactorial and 
are partially driven by a patient’s general condi-
tion. The increase in left atrial size may represent 
elevated filling pressures, even though it is not 
solely dependent on diastolic pressure, particularly 
in transplanted hearts. Interestingly, systolic blood 
pressure was reduced at the time of PeEf. It is well 
known, that a reduced systolic blood pressure is as-
sociated with negative prognosis in multiple clinical 
settings, such as heart failure [21], infection [22], 
pulmonary embolism [23], and myocardial infarc-
tion [24]. In light of this, the differences in NYHA 
class and blood pressure are most likely multifacto-
rial and may be considered a marker for increased 
morbidity in general. The reduction in TAPSE was 
also significant. However, in contrast to the other 
parameters quantitative change and patients having 
measured TAPSE at both time points was low, so 
that it seems clinically negligible. As expected in 
transplanted patients, relevant tricuspid regurgita-
tion was more frequent in patients having a PeEf 
at a later stage (> 12 years after transplantation), 
suggesting that in these situations tricuspid dys-
function may be more relevant in contributing to 
PeEf than in patients at earlier stages.
Hypothesizing that PeEf could be related to 
malignancy, analysis of the temporal context of 
PeEf and the time of diagnosis of malignant tumors 
was also performed. However, no association pat-
tern was evident, suggesting that even though 
cancer was the leading cause of death in this 
population, most PeEf were not of malignant origin. 
Similarly, C-reactive protein was comparable at 
both time points (baseline and PeEf), even though 
infection was the second most common cause of 
death. Hence, neither tumors nor infections seem 
to induce a PeEf in a direct manner, again pointing 
to the interpretation that the occurrence of a small 
PeEf in a transplant recipient is a general marker 
of increased mortality and morbidity.
Immunosuppressant medication was compara-
ble during baseline and at the time of PeEf with the 
exception of sirolimus. The latter was described to 
be associated with PeEf in a small study (4 PeEf 
in 25 patients) [25]. In the present population, it 
was part of the medication in 3 patients with PeEf 
whereas it was not prescribed at baseline. Hence, 
sirolimus may at least in part account for the PeEf 
in these 3 patients.
Taking all these data into account, this study 
suggests that the etiology of PeEf is variable and 
may often be multifactorial (heart failure, malig-
nancy, infection, and others), suggesting that the 
finding of PeEf in a heart transplant patient should 
lead to further investigation for excluding poten-
tially treatable pathologies not necessarily related 
to cardiac function per se.
Limitations of the study
Given the observational, retrospective study 
design, the limitation of this study is a possible 
confounding bias (taking into account that echocar-
diograms were performed during regular follow-up 
as well as for clinical reasons) additionaly the prob-
lem of informative but missing measurements of 
patients not requiring medical care or those being 
examined in other hospitals. 
Conclusions
In summary, this study reveals that the echo-
cardiographic finding of a hemodynamically irrel-
evant PeEf in heart transplant patients is a predic-
tor of adverse outcome, evidenced by a 2.5 times 
higher risk of both death and hospitalization. Thus, 
a small PeEf — which may be observed during 
routine echocardiography — should be regarded as 
a “red flag”, leading to further examination of the 
patient with a focus on potentially treatable causes 
not directly related to the pericardial effusion.
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